Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 3/2018

01-09-2018 | Case Report

A Case Report—Stevens-Johnson Syndrome as an Adverse Effect of Capecitabine

Authors: Priyanka Jadhav, Jane E. Rogers, Rachna Shroff

Published in: Journal of Gastrointestinal Cancer | Issue 3/2018

Login to get access

Excerpt

Stevens-Johnson syndrome, SJS, is a rare but deadly disease with a 30% mortality rate that increases after the first year. It is closely related to toxic epidermal necrolysis, the primary differentiating factor being that SJS presents with more severe skin detachment. Initially, flu-like symptoms including fever greater than 102 °F and chills lead to rash manifestation accompanied by blisters, sores, and a burning sensation [1]. Mucosal lesions are present in 90% of patients, originating on the face and thorax before spreading. While the complete pathogenesis of SJS is not understood, it is thought that the cell-mediated cytotoxic reaction against the native drug form that binds to MHC1 and T cell receptors causes apoptosis of keratinocytes. The top layer of the affected skin area dies and sheds, the severity of which determines the length of the course of treatment for the patient. Predisposing factors include human immunodeficiency virus, underlying immunological conditions, or genetic factors including HLA in the Asian population and a polymorphism in the CYP2C19 gene [2]. …
Literature
1.
go back to reference Plaza JA. Erythema multiforme-background, pathophysiology, etiology. N.p., 24 May 2016. 13 Aug. 2016. Plaza JA. Erythema multiforme-background, pathophysiology, etiology. N.p., 24 May 2016. 13 Aug. 2016.
2.
go back to reference Stevens-Johnson syndrome. Causes. N.p., n.d. Web. 13 Aug. 2016. Stevens-Johnson syndrome. Causes. N.p., n.d. Web. 13 Aug. 2016.
5.
go back to reference Sendur MA, Kilickap S. Stevens-Johnson síndrome after treatment with capecitabine. Clin Oncol (R Coll Radiol). 2008;20(2):202–3.CrossRef Sendur MA, Kilickap S. Stevens-Johnson síndrome after treatment with capecitabine. Clin Oncol (R Coll Radiol). 2008;20(2):202–3.CrossRef
Metadata
Title
A Case Report—Stevens-Johnson Syndrome as an Adverse Effect of Capecitabine
Authors
Priyanka Jadhav
Jane E. Rogers
Rachna Shroff
Publication date
01-09-2018
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 3/2018
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-016-9916-3

Other articles of this Issue 3/2018

Journal of Gastrointestinal Cancer 3/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.